
    
      A study to evaluate the effect of 24 weeks of subcutaneous (SC) evolocumab compared with
      placebo, when added to standard of care, on percent change from baseline in low-density
      lipoprotein cholesterol (LDL-C) in pediatric subjects 10 to 17 years of age with heterozygous
      familial hypercholesterolemia (HeFH).
    
  